<?xml version="1.0" encoding="UTF-8"?>
<results title="country">
 <result pre="University Medical Center UtrechtUtrechtNetherlands Edited by: Sandor Kerpel-Fronius, Semmelweis University," exact="Hungary" post="Reviewed by: Rolf Bass, Retired, Berlin, Germany; Annette Mollet,"/>
 <result pre="Rolf Bass, Retired, Berlin, Germany; Annette Mollet, University of Basel," exact="Switzerland" post="*Correspondence: Annemiek van Rensen a.vanrensen@pgosupport.nl This article was submitted"/>
 <result pre="further roll-out of the Dutch version of EUPATI in the" exact="Netherlands" post="and the agreements on collaboration between involved stakeholders that"/>
 <result pre="academic world, and industry. All participants were based in the" exact="Netherlands" post="and familiar with the Dutch medicine R&amp;amp;D context. Table"/>
 <result pre="- no professional affiliation with medicine R&amp;amp;D Governmental organizations 3" exact="Netherlands" post="Pharmacovigilance Centre (Lareb) Analyzes the risks associated with medicines"/>
 <result pre="with an established training facility for patient representatives in the" exact="Netherlands" post="since 2008â€&quot;would be the designated organization to lead the"/>
 <result pre="indirectly add to the incentive for patient involvement in the" exact="Netherlands" post="in general. As such, this is in line with"/>
 <result pre="and directed at patient representatives, will become available in the" exact="Netherlands" post="for the first time. Benefits Extend the Aspect of"/>
 <result pre="Values for a EUPATI Network and Training Program in the" exact="Netherlands" post="Stakeholders identified important key values and principles at an"/>
 <result pre="in this study: The Dutch Patient Federation (PF), EUPATI fellows," exact="Netherlands" post="Pharmacovigilance Center (Lareb), Medicines Evaluation Board (CBG-MEB), National Health"/>
</results>
